First-in-human trial of GB268 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug called GB268, which targets three different proteins (PD-1, CTLA-4, and VEGF) that help tumors grow and hide from the immune system. It is for people with advanced solid tumors who have tried standard treatments, or for whom no standard treatment is available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Advanced or metastatic solid tumor that has not responded to standard therapy, or for which no standard therapy exists
- Able to have daily activities without major help (ECOG score 0 or 1)
- Life expectancy of at least 3 months
- Good organ function as shown by blood tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study drug, GV20-0251, for people with advanced solid tumors that no longer respond to standard therapies. It aims to see if the drug can shrink tumors or slow their growth.
This study tests a new drug (BGB-26808) alone or with another drug (tislelizumab) for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if the combination can help shrink tumors or slow their growth.
This trial tests a new drug called GB268, either alone or with other treatments, for people with advanced breast cancer that has not responded to previous therapies. It aims to find out if GB268 can help shrink tumors or slow the cancer's growth.
This trial tests a new drug called VBC106 for people with advanced solid tumors that have not responded to other treatments. It is the first time this drug is being tested in humans, and aims to see if it is safe and helps shrink tumors.
This trial tests a new drug called HBT-708 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and how the body handles it.
This trial tests a new drug (GRWD5769) that may help your immune system fight cancer. It is for people with advanced solid tumors that have stopped responding to standard treatments, including certain types of cervical, liver, and other cancers.
Hear when a new Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.